In patients with impaired renal function or fast-deteriorating eGFR at baseline, lucerastat was associated with a marked attenuation of kidney function loss, suggesting a potential disease-modifying effect. The company is… Read More
VANCOUVER, BC – AbCellera announced that the first patients have been dosed in the Phase 2 portion of its ongoing Phase 1/2 clinical trial for ABCL635. ABCL635 is a potential first-in-class… Read More
Positive Phase 3 HERIZON-GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone payments eligible to be earned related to regulatory approvals… Read More
Turner is proud to commemorate 100 years of building healthcare facilities that support lifesaving care, foster healing, and bring comfort to patients and their families. As a leading healthcare builder… Read More
The following article was originally published by the University of British Columbia Faculty of Medicine. For the first time, researchers at UBC have demonstrated how to reliably produce an important type of human… Read More
